impact factor

Full Papers


Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study

1, 2, 3, 4, 5, 6, 7


  1. School of Medicine, Griffith University, Queensland, Australia.
  2. Swedish Medical Centre/Providence St. Joseph Health and University of Washington, Seattle, USA.
  3. Guy’s & St Thomas’ NHS Foundation Trust, London, UK.
  4. Southwest Rheumatology, Dallas, USA.
  5. Novartis Pharma AG, Basel, Switzerland.
  6. Novartis Pharmaceuticals Corporation, East Hanover, USA.
  7. Novartis Pharma AG, Basel, Switzerland.

2022 Vol.40, N°5
PI 0952, PF 0959
Full Papers

purchase article

PMID: 34494957 [PubMed]

Received: 03/02/2021
Accepted : 26/04/2021
In Press: 03/09/2021
Published: 13/05/2022


To evaluate the impact of secukinumab on nail psoriasis and other psoriatic disease manifestations in patients with psoriatic arthritis (PsA) with concomitant nail psoriasis from the FUTURE 5 study.
Eligible patients were randomly allocated to receive subcutaneous secukinumab (300 mg load [300 mg], 150 mg load [150 mg], and 150 mg [no load]) or placebo weekly and then every 4 weeks starting Week 4. Key assessments through Week 104 in this post hoc analysis included modified Nail Psoriasis Severity (mNAPSI), Psoriasis Area and Severity Index (PASI 90), resolution of dactylitis and enthesitis, Dermatology Life Quality Index (DLQI) and radiographic progression (assessed by vdH-mTSS).
At baseline, 66.6% patients (663/996) had concomitant nail psoriasis. Baseline characteristics were balanced in the nail subset and comparable with the overall population. Secukinumab reduced mNAPSI score at Week 16 versus placebo: -8.71 (300 mg), -8.95 (150 mg), -7.55 (150 mg no load) versus -2.34 (placebo); all p<0.0001. Mean change from baseline in DLQI at Week 16 was -8.5 (300 mg), -7.4 (150 mg), -7.3 (150 mg no load) versus -2.4 (placebo); all p<0.0001. Overall, the improvements reported at Week 16 sustained through Week 104. The proportion of patients with no radiographic progression (change from baseline in vdH-mTSS≤0.5) at Week 104 was 91.9% (300 mg) 78.9% (150 mg), and 82.4% (150 mg no load).
Secukinumab provided sustained improvements in nail disease, signs and symptoms of PsA, and a low rate of radiographic progression through 2 years in patients with concomitant nail psoriasis.


Rheumatology Article

Rheumatology Addendum